Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer
No new safety signals occurred with neoadjuvant pertuzumab/trastuzumab at five years
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer
AC-KP did not result in improved efficacy in any reasonably sized biomarker subgroup
Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive Early Breast Cancer
Non-inferiority with the short- versus long-term adjuvant trastuzumab could not be claimed
The RAD51-IF Test Is Feasible for Assessment of the Functional Status of Homologous Recombination Repair in TNBC Tumours
Results from two studies support further development to incorporate RAD51 testing in clinical decision making
Atezolizumab with Carboplatin as Immune Induction Shows Promise in Metastatic Lobular Breast Cancer
Findings from the GELATO study
Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays Onset of Progression in mCSPC
Findings from the final analysis of the TITAN study in patients with metastatic castration-sensitive prostate cancer
Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical Cancer
After publication of the LACC study results, reduction in robotic or laparoscopic surgery is mainly seen in academic centres
EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate
Abiraterone KRKA is a generic of Zytiga, which has been authorised in the EU since 2011
EMA Recommends Granting a Marketing Authorisation for Azacitidine
It is intended for the maintenance treatment of patients with acute myeloid leukaemia
EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib
It is intended for the treatment of paediatric patients with NF1 plexiform neurofibromas
FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma
Approval is based on findings from the LOTIS-2 study
EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab
New indication concerns their combination in the first-line treatment of adult patients with unresectable malignant pleural mesothelioma